Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.64 USD

18.64
7,091,998

+0.19 (1.03%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $18.64 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.

Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

by Zacks Equity Research

The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

by Zacks Equity Research

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $16.64, marking a +0.79% move from the previous day.

BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up

by Zacks Equity Research

BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.

Insys Plunges on Auditor's Concern About Insufficient Funds

by Zacks Equity Research

Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.

Allergan Announces FDA Acceptance of Migraine Candidate NDA

by Zacks Equity Research

Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.

Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.78, marking a +0.19% move from the previous day.

Lilly's Emgality Gets FDA Priority Review for Cluster Headache

by Zacks Equity Research

Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.

Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down

by Zacks Equity Research

Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.

Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA

by Zacks Equity Research

The FDA accepts Alkermes (ALKS) and partner Biogen's NDA for diroximel fumarate and sets an action date in the fourth quarter of 2019.

Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.

Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when the company reports Q4 results.

Allergan Responds to Investor's Call for CEO/Chair Role Split

by Zacks Equity Research

Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.

Pfizer & Lilly's Pain Candidate Succeeds in Back Pain Study

by Zacks Equity Research

Pfizer (PFE) and Eli Lilly (LLY) announce that the higher dose of their investigational pain candidate, tanezumab, significantly reduces chronic low back pain in a late-stage study.

What's in the Cards for Amarin (AMRN) This Earnings Season?

by Zacks Equity Research

Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.

Teva (TEVA) Q4 Earnings Miss,'19 View Weak, Shares Down

by Zacks Equity Research

Teva's (TEVA) fourth-quarter earnings miss estimates while sales marginally beat expectations. Guidance for 2019 is lower than expected.

Key Takeaways from Eli Lilly's (LLY) Q4 Earnings Report

by Zacks Equity Research

Here are the key takeaways from Eli Lilly's (LLY) fourth-quarter earnings conference call.

Earnings & Data Deluge

by Zacks Equity Research

Earnings & Data Deluge

Mark Vickery headshot

Markets Keeping Optimistic... For Now; Plus HLT, TEVA, DISH

by Mark Vickery

Pre-market futures are again trading up today, as expectations continue to be favorable for two things that have yet to be officially resolved.

Teva (TEVA) Misses on Q4 Earnings, Beats Sales, Shares Down

by Zacks Equity Research

Teva's (TEVA) fourth-quarter earnings misses estimates but sales beat expectations. Teva???s sales and earnings guidance for 2019 is weaker than expected.

Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $18.22, marking a -0.71% move from the previous day.

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

by Zacks Equity Research

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.